Respiratory syncytial virus sequencing considerations for an expanded Global Influenza Surveillance and Response System
World Health Organization
lip 2025. · World Health Organization
E-knjiga
35
str.
family_home
Ispunjava uvjete
info
reportOcjene i recenzije nisu potvrđene Saznajte više
O ovoj e-knjizi
In recent years, rapid progress has been made in the development of new pharmaceutical interventions against respiratory syncytial virus (RSV), including monoclonal antibodies (mAbs), vaccines and antivirals. Both passive immunization and active immunization against RSV have now been recommended for infants and older adults in several countries. The ongoing surveillance of RSV viruses is thus vital for identifying the appropriateness of diagnostics and interventions. Establishing a baseline understanding of RSV sequence diversity prior to the widespread rollout of immunization will help to inform the development of new diagnostic and therapeutic products, facilitate assessment of the effectiveness of immunization programmes, better understand viral diversity and evolution, and assess the potential impact of RSV variants on the effectiveness of interventions. This document outlines a number of practical considerations regarding the scale and quality of sequencing. It also outlines the range of next generation sequencing (NGS) technologies suitable for RSV whole genome sequencing (WGS).
Ocijenite ovu e-knjigu
Recite nam što mislite.
Informacije o čitanju
Pametni telefoni i tableti
Instalirajte aplikaciju Google Play knjige za Android i iPad/iPhone. Automatski se sinkronizira s vašim računom i omogućuje vam da čitate online ili offline gdje god bili.
Prijenosna i stolna računala
Audioknjige kupljene na Google Playu možete slušati pomoću web-preglednika na računalu.
Elektronički čitači i ostali uređaji
Za čitanje na uređajima s elektroničkom tintom, kao što su Kobo e-čitači, trebate preuzeti datoteku i prenijeti je na svoj uređaj. Slijedite detaljne upute u centru za pomoć za prijenos datoteka na podržane e-čitače.
